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More than 30 % of patients with colorectal 
cancer developed liver metastases. 
Radical surgical resection of liver 
metastases remains the only chance of 
cure with more than 50% 5-year survival. 
Unfortunately, most of the patients are 
presented with unresectable metastases 
because of their size, number, location or 
inadequate liver remnant after resection. 
In unresectable disease, many ablative 
approaches can be used. The most 
frequent is radiofrequency ablation(RFA). 
However, RFA is less effective in the 
treatment of metastases in the vicinity of 
major hepatic vessels due to heat sink 
effect. 
From 2009 to 2018 35 patients with 
colorectal liver metastases were 
treated with electrochemoterapy at 
our department. In our first published 
analyses, 29 metastases in 16 patients 
were treated with electrochemoterapy 
during open surgery by US-guided 
insertion of long needle electrodes (with 
variable or fixed geometry) into and 
around the tumor. Up to three metastases 
not exceeding 3 cm in the diameter were 
treated with electrochemoterapy. Patients 
were divided into three groups. In the 
first two groups were patients with two-
stage liver surgery. In the first operation, 
some of the metastases were treated 
by electrochemoterapy and removed 
during the second operations. In the 
third group patients with unresectable 
metachronous metastases were treated 
with electrochemoterapy as the only 
treatment option. 
There was no perioperative mortality. 
Three patients required reoperation after 
electrochemoterapy; two because of 
colon perforation and one because of 
obstruction of small bowel because of 
adhesions. None of these complications 
were related to electrochemoterapy. 
During or after electrochemoterapy no 
major heart rhythm changes or myocardial 
ischemia were found. 
Radiological complete response was 
observed in 85% of treated metastases 
and partial in 15% after the first 
radiological evaluation. At the second 
evaluation, at a median of 147 days after 
electrochemoterapy, 71% of metastases 
were still in complete response. Response 
to electrochemoterapy was the same in 
metastases located close to major hepatic 
vessels and metastases away from the 
vessels. On pathological analysis, non 
treated metastases had a significantly 
higher percentage of residual viable tumor 
compared to electrochemoterapy treated. 
We found regressive changes in the whole 
electrochemoterapy-treated area of the 
liver with disruption of vessels less than 
5 mm in diameter and preservation of the 
larger vessels and biliary ducts. 
Electrochemoterapy of liver metastases 
is feasible, efficient and safe treatment 
modality, especially for the metastases in 
the vicinity of major hepatic vessels.
